Ind-Swift Laboratories Q1FY27 PAT surges 2.04x to ₹24.68 crore
Ind-Swift Laboratories delivered strong Q1FY27 results with PAT rising 2.04x YoY to ₹24.68 crore and EBITDA margins expanding to 17.91%. The performance was driven by operational efficiencies and new CDMO partnerships with Viatris and Manx, which are expected to add ₹200-220 crore in revenue this fiscal year.
*this image is generated using AI for illustrative purposes only.
Ind-Swift Laboratories reported a robust start to FY27, with standalone profit after tax (PAT) excluding exceptional items rising 2.04 times year-on-year to ₹24.68 crore in Q1FY27, compared to ₹8.12 crore in the corresponding period of the previous year. The company’s operating EBITDA surged 2.85 times to ₹33.32 crore from ₹8.66 crore, driven by a significant expansion in operating margins and improved business mix. This performance underscores the company’s successful transition into a focused, debt-free formulations platform.
Standalone Financial Performance
The standalone results for the quarter ended June 30, 2026, highlight substantial improvements in profitability metrics. Operating income grew by 21.16% year-on-year to ₹186.08 crore from ₹153.58 crore. The most notable improvement was seen in the operating EBITDA margin, which expanded by 1,258 basis points (bps) to 17.91% from 5.33% in Q1FY26. Similarly, the PAT margin improved by 827 bps to 13.26% from 4.99%.
| Metric: | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Operating Income: | ₹186.08 crore | ₹153.58 crore | ↑ 21.16% |
| Op. EBITDA: | ₹33.32 crore | ₹8.66 crore | ↑ 2.85x |
| Op. EBITDA Margin: | 17.91% | 5.33% | ↑ 1,258 bps |
| PAT (excl. exceptional): | ₹24.68 crore | ₹8.12 crore | ↑ 2.04x |
| PAT Margin: | 13.26% | 4.99% | ↑ 827 bps |
Operational Milestones and Growth Drivers
Chairman N.R. Munjal attributed the strong quarterly performance to better efficiencies, an improved business mix, and disciplined execution. The company has successfully transformed into a net-debt-free, pure-play formulations platform with a global footprint spanning over 85 countries. Key operational milestones during the quarter included the commercialization of two products: Ibuprofen Sachet for the European market and Macrogol Sachet for the UK and Australia markets.
A significant growth driver is the newly commercialized Contract Development and Manufacturing Organization (CDMO) partnership with Viatris (USA), Manx (UK), and Arrotex (Australia). This partnership is expected to contribute an incremental ₹200-220 crore of revenue in FY27. Additionally, the company’s global dossier pipeline expanded, with filed dossiers rising to over 2,100 from 1,915 earlier, and product registrations growing to over 900 from 750.
Strategic Initiatives and Future Outlook
Ind-Swift Laboratories is currently upgrading its Samba manufacturing facility to EU-GMP and PIC/S standards. This investment aims to enhance export capabilities, support filings across regulated markets, and strengthen long-term growth visibility. On the domestic front, the company is targeting a 15-20% compound annual growth rate (CAGR) by expanding its ethical footprint into peninsular India and high-growth chronic therapeutic categories.
Looking ahead, management expects FY27 to witness revenue growth of more than 50%, supported by own-brand growth internationally and deeper penetration in markets such as UAE and Central Asia. The company also projects a medium-term revenue CAGR of 20-25%, alongside further EBITDA margin expansion of 600-800 bps driven by operating leverage and an improved business mix.
What the Numbers Show
The shift in revenue mix towards higher-margin segments is evident in the financials. While domestic segments like Branded Generics and Ethical Division saw their share of total sales decline slightly from 17% in Q1FY26 to 12.55% in Q1FY27, the Export Own-Brands segment increased its share from 48% to 57.20%. This pivot towards high-margin export own-brands, combined with the new CDMO partnerships, appears to be the primary driver behind the 1,258 bps expansion in operating EBITDA margins, despite a modest 21.16% growth in operating income.
Historical Stock Returns for Ind Swift Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.90% | +37.03% | +36.17% | +117.75% | +208.56% | +318.73% |
How will the EU-GMP and PIC/S certification of the Samba facility specifically impact Ind-Swift's ability to secure contracts in highly regulated Western markets beyond the current CDMO partnerships?
What are the potential risks associated with the rapid expansion of the global dossier pipeline to over 2,100 filings, particularly regarding regulatory approval timelines and associated R&D costs?
Given the projected 50%+ revenue growth for FY27, how does management plan to sustain the targeted 600-800 bps EBITDA margin expansion amidst potential currency fluctuations in key export markets like UAE and Central Asia?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
